期刊文献+

甲状腺外科疾病的生物治疗

Biotherapy in the treatment of surgical disorders of the thyroid
下载PDF
导出
摘要 随着分子生物学技术的发展,疾病的生物学治疗是目前医学研究重点之一.有关甲状腺外科疾病的生物治疗取得了许多突破性结果.本文对近年来本领域生物治疗研究的一些热点进行介绍.
出处 《外科理论与实践》 2005年第6期497-499,共3页 Journal of Surgery Concepts & Practice
  • 相关文献

参考文献19

  • 1Ando T,Latif R,Pritsker A,et al. A monoclonal thyroidstimulating antibody[J]. J Clin Invest,2002,110(11):1667-1674.
  • 2Sanders J,Jeffreys J,Depraetere H,et al. Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function[J]. Thyroid,2004,14(8):560-570.
  • 3Sanders J,Allen F,Jeffreys J,et al. Characteristics of a monoclonal antibody to the thyrotropin receptor that acts as a powerful thyroid-stimulating autoantibody antagonist[J]. Thyroid,2005,15(7):672-682.
  • 4Cocks HC,Thompson S,Turner FE,et al. Role and regulation of the fibroblast growth factor axis in human thyroid follicular cells[J]. Am J Physiol Endocrinol Metab,2003,285(3):E460-469.
  • 5Davies EL,Ramsden JD,Cocks H,et al. Adenovirusmediated expression of dominant negative fibroblast growth factor(FGF)receptor 1 in thyroid cells blocks FGF effects and reduces goitrogenesis in mice[J]. J Clin Endocrinol Metab,2003,88(9):4472-4480.
  • 6Ramsden JD,Buchanan MA,Egginton S,et al. Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin,vascular endothelial growth factor,and fibroblast growth factor signaling[J].Endocrinology,2005,146(7):2895-2902.
  • 7Nagayama Y,Nishihara E,Namba H,et al. Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system[J]. Cancer Gene Ther,2001,8(1):36-44.
  • 8Kim SB,Ahn IM,Park HJ,et al. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line(NPA)transfected with p53 gene[J]. Head Neck,2001,23(3):223-229.
  • 9Barzon L,Gnatta E,Castagliuolo I,et al. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma[J]. Cancer Gene Ther,2005,12(4):381-388.
  • 10Imanishi R,Ohtsuru A,Iwamatsu M,et al. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy[J]. J Clin Endocrinol Metab,2002,87(10):4821-4824.

二级参考文献8

  • 1[1]O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth.Cell,1997,88(2):277
  • 2[2]Gasparini G.The rationale and future potential of angiogenesis inhibitors in neoplasia.Drugs,1999,58(1):17
  • 3[3]Lennard CM, Patel A, Wilson J, Reinhardt B, et al.Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer.Surgery,2001,129(5):552
  • 4[4]Huang SM, Lee JC, Wu TJ,et al.Clinical relevance of vascular endothelial growth factor for thyroid neoplasms.World J Surg,2001,25(3):302
  • 5[5]Akslen LA, Livolsi VA.Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol,2000,31(4):439
  • 6[6]Soh EY, Eigelberger MS, Kim KJ,et al.Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.Surgery,2000,128(6):1059
  • 7[7]Belletti B, Ferraro P, Arra C, et al.Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene,1999,18(34):4860
  • 8[8]Feldman AL, Alexander HR, Hewitt SM, et al.Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J Natl Cancer Inst,2001,93(13):1014

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部